For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > REGULATORY
REGULATORY
- Lilly Drops Listing of Taltz amid Pricing Fuss, Wants to Deliver Drug without Restrictions
August 31, 2016
- MHLW Panel to Discuss Keytruda on Sept. 9, Listing Expected as Early as November
August 30, 2016
- MHLW Unveils FY2017 Budget Request, 105.8 Bil. Yen Sought for Healthcare Innovation
August 29, 2016
- MHLW Requests Extension of R&D Tax Credit for “High-Level Investment”
August 29, 2016
- MHLW OKs RCC Indication for Opdivo, Approval Changes to Other Drugs
August 29, 2016
- AZ’s Ticagrelor, BI’s Triple Combo to Take Another Stab to Clear MHLW Committee
August 26, 2016
- MHLW Advisory Committee to Review Reversal Agent for Prazaxa on Sept. 7
August 26, 2016
- MHLW Grants Orphan Status to Crizotinib, 3 Other Drugs
August 26, 2016
- Innovative Drugs Are Not “Villain,” Kamoya Laments
August 25, 2016
- Chuikyo Subcommittee Effectively Kicks Off Debates on FY2018 Reform, with Focus on Pricy Meds
August 25, 2016
- Discussions on Opdivo’s Special Pricing Measure Get Underway at Chuikyo Subcommittee
August 25, 2016
- After Taltz Given High Price, MHLW to Push Use of Other Psoriasis Drugs; Revision to Foreign Price Adjustment Eyed
August 25, 2016
- MHLW to Set Up Dedicated Office for Antimicrobial Resistance: FY2017 Budget
August 24, 2016
- MHLW to Seek 2 Billion Yen to Foster Healthcare Startups in FY2017
August 24, 2016
- Chuikyo OKs Praluent, 8 Other APIs for Listing on Aug. 31
August 24, 2016
- Basic Policies for JP 18th Edition Now Up for Public Comments
August 23, 2016
- Japan to Target 95-100% SVR for Hep C, Compensated Cirrhosis in Revised 10-Year Strategy
August 23, 2016
- MHLW to Seek Funding to Promote and Support Healthcare Startups in FY2017 Budget Request
August 23, 2016
- MHLW to Seek Budgets to Develop Artificial Intelligence for Drug Discovery
August 22, 2016
- Japanese Pharmacopoeia 17th Edition Now Available in English
August 22, 2016
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…